SeekingAlpha · Aug 11, 2026
TELA Bio, Inc. (TELA) Q2 2026 Earnings Call Transcript
TELA Bio, Inc. (TELA) Q2 2026 Earnings Call August 10, 2026 4:30 PM EDTCompany ParticipantsLouisa Smith - Investor Relations Contact OfficerJoseph...
TE
NASDAQ · TELA
TELA Bio, Inc.
Healthcare · Medical - Devices
$0.65
Up+$0.01 (+1.09%)
Updated Aug 24, 2026, 12:44 AM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 45.56M
- P/E ratio
- -1.32
- Dividend yield
- 0.00%
- 52-week range
- $0.50 – $1.27
- Volume
- 59.8K
- Avg. volume
- 183.24K
Price performance
TELA price history
1M range · 0 trading sessions · Daily adjusted prices
TELA does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
Latest TELA news
The latest Smart Investors Daily articles mentioning TELA.
Stock researchCompany · Overview
TELA research
Overview
Company profile and research snapshot.
Company profile
TELA Bio Inc a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions that optimize clinical outcomes by prioritizing the preservation and restoration of the patient's anatomy. Its growing product portfolio is purposefully designed to leverage the patient's natural healing response while minimizing long-term exposure to permanent synthetic materials. The company's OviTex portfolio consists of multiple product configurations intended to address various surgical procedures within hernia repair and abdominal wall reconstruction, including ventral, inguinal, and hiatal hernia repair.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- —
- Average target
- $2.42
- Implied upside
- —
- Analysts
- —
| Date | Firm | Rating | Target |
|---|---|---|---|
| Mar 27, 2026 | Citizens | Market Outperform | — |
| Mar 25, 2026 | Lake Street | Buy | — |
| Mar 25, 2026 | Piper Sandler | Neutral | — |
| Mar 25, 2026 | Canaccord Genuity | Buy | — |
| Dec 1, 2025 | Lake Street | Buy | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 10, 2026
TELA Bio Q2 EPS $(0.20) Misses $(0.18) Estimate, Sales $19.291M Miss $20.008M Estimate
TELA Bio (NASDAQ:TELA) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.18) by 11.11 percent. This is a 9.09 percent increase over losses of $(0.22) per share from the
Benzinga · Aug 4, 2026
TELA Bio Appoints Heather Getz CEO, Effective Immediately
TELA Bio, Inc. ("TELA Bio" or the "Company"), a commercial-stage medical technology company focused on providing innovative soft-tissue reconstruction solutions, announced that the Board of Directors
Benzinga · Jun 25, 2026
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers Adicet Bio (NASDAQ:ACET) stock moved upwards by 22.9% to $10.14 during Thursday's pre-market session. The market value of their outstanding shares is at $77.1 million. Bio-Techne (NASDAQ:TECH) stock moved
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
